Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (GTHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 233,330
  • Shares Outstanding, K 52,199
  • Annual Sales, $ 82,510 K
  • Annual Income, $ -47,970 K
  • 60-Month Beta 1.70
  • Price/Sales 2.71
  • Price/Cash Flow N/A
  • Price/Book 6.07
Trade GTHX with:

Options Overview Details

View History
  • Implied Volatility 101.95% ( -19.96%)
  • Historical Volatility 114.42%
  • IV Percentile 3%
  • IV Rank 10.87%
  • IV High 703.89% on 10/13/23
  • IV Low 28.56% on 08/16/23
  • Put/Call Vol Ratio 0.10
  • Today's Volume 564
  • Volume Avg (30-Day) 887
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 35,977
  • Open Int (30-Day) 40,098

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.19
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.20
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +64.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +47.29%
on 03/18/24
4.76 -9.34%
on 03/27/24
+0.99 (+29.73%)
since 02/28/24
3-Month
2.01 +114.93%
on 02/13/24
5.00 -13.60%
on 02/08/24
+1.29 (+42.57%)
since 12/28/23
52-Week
1.08 +300.00%
on 10/09/23
5.00 -13.60%
on 02/08/24
+1.68 (+63.64%)
since 03/28/23

Most Recent Stories

More News
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 17.19% and 22.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

GTHX : 4.32 (-3.36%)
MRSN : 4.48 (-0.22%)
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BMRN : 87.34 (-1.43%)
GTHX : 4.32 (-3.36%)
G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade

G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GTHX : 4.32 (-3.36%)
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

GTHX : 4.32 (-3.36%)
AGLE : 12.01 (+8.79%)
Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 10.52 (+2.14%)
GTHX : 4.32 (-3.36%)
G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GTHX : 4.32 (-3.36%)
First Prescription for COSELA® (trilaciclib) Issued in China

/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:...

GTHX : 4.32 (-3.36%)
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...

ONC.TO : 1.45 (+5.07%)
ONCY : 1.0600 (+2.91%)
LLY : 777.96 (-0.03%)
NEO : 15.72 (+3.42%)
ZYME : 10.52 (+2.14%)
GTHX : 4.32 (-3.36%)
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)

EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END

ONCY : 1.0600 (+2.91%)
ONC.TO : 1.45 (+5.07%)
LLY : 777.96 (-0.03%)
NEO : 15.72 (+3.42%)
ZYME : 10.52 (+2.14%)
GTHX : 4.32 (-3.36%)
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year’s...

ONCY : 1.0600 (+2.91%)
ONC.TO : 1.45 (+5.07%)
LLY : 777.96 (-0.03%)
NEO : 15.72 (+3.42%)
ZYME : 10.52 (+2.14%)
GTHX : 4.32 (-3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 4.91
2nd Resistance Point 4.79
1st Resistance Point 4.55
Last Price 4.32
1st Support Level 4.19
2nd Support Level 4.07
3rd Support Level 3.83

See More

52-Week High 5.00
Last Price 4.32
Fibonacci 61.8% 3.50
Fibonacci 50% 3.04
Fibonacci 38.2% 2.58
52-Week Low 1.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar